

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Stearoyl-L-carnitine (chloride)

Item No. 26556

CAS Registry No.: 32350-57-5

Formal Name: 3-carboxy-N,N,N-trimethyl-2R-[(1-

oxooctadecyl)oxy]-1-propanaminium,

monochloride

Synonyms: C18 Carnitine,

Octadecanoyl-L-carnitine,

R-Stearoyl carnitine


MF: C₂₅H₅₀NO₄ • CI

FW: 464.1 **Purity:** ≥95%

A crystalline solid Supplied as:

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Stearoyl-L-carnitine (chloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the stearoyl-L-carnitine (chloride) in the solvent of choice. Stearoyl-L-carnitine (chloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of stearoyl-L-carnitine (chloride) in ethanol and DMF is approximately 20 mg/ml and approximately 14 mg/ml in DMSO.

Description

Stearoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. 1 It inhibits sodium-dependent [3H]carnitine uptake in human proximal convoluted tubular (HPCT) cells by 52% when used at a concentration of 500 μM.² It also inhibits lecithin:cholesterol acyltransferase activity in rat, but not human, plasma when used at a concentration of 500 µM/ml of plasma.³ Plasma levels of stearoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.^{1,4}

References

- 1. Reuter, S.E., Evans, A.M., Faull, R.J., et al. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann. Clin. Biochem. 42(Pt 5), 387-393 (2005).
- 2. Huang, W., Shaikh, S.N., Ganapathy, M.E., et al. Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cells. Biochem. Pharmacol. 58(8), 1361-1370 (1999).
- Bell, F.P. Carnitine esters: Novel inhibitors of plasma lecithin: Cholesterol acyltransferase in experimental animals but not in man (Homo sapiens). Int. J. Biochem. 15(2), 133-136 (1983).
- Reuter, S.E. and Evans, A.M. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J. Intern. Med. 270(1), 76-84 (2011).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/15/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM